FRNM - Freenome, Inc. So'nggi Yangiliklar | Finranks

12.08.2026

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to SimpleScreen™ Lung, the company's investigational lung cancer screening test.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
FRNM	Guggenheim	Buy	undefined >> $21	August 20th 2026
FRNM	TD Cowen	Buy	undefined >> $17	August 18th 2026
FRNM	Jefferies	Buy	undefined >> $17	August 17th 2026
FRNM	BTIG Research	Buy	undefined >> $17	August 17th 2026
FRNM	Leerink Partners	Outperform	undefined >> $18	August 14th 2026

Press-relizlar

12.08.2026

Freenome, Inc. (FRNM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Freenome, Inc. (FRNM)

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

Search stocks

Freenome, Inc. (FRNM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Freenome, Inc. (FRNM)

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test